# Forensic Dossier: Study Forensics: Novel cholesterol drug dramatically lowers LDL but cardiovascular outcomes unknown

**Run ID:** `ocfix_study-forensics-032_Claude_Haiku_34bb32`  
**Task:** study-forensics-032 | study_forensics | medium | study_forensics  
**Timestamp:** 2026-04-08T17:27:41.042642+00:00  
**Task Family:** overclaim  
**Trap Type:** surrogate_endpoint_overclaim  
**Ambiguity:** low  

## Executive Summary

**Agents tested:** Claude Haiku
**Winner:** Claude Haiku — **70.6/100** (margin: 0.0)
**Failure modes:** decorative_uncertainty, missed_key_insight, oververbose_without_gain, unsupported_conclusion, unsupported_intermediate_step
**Forensic flags:** 3
**Consistency findings:** 6
**Answer convergence:** all agents agree

## Score Matrix

| Agent | Correctness | Support Strength | Structural Reaso | Assumption Disci | Uncertainty Hand | Alternative Hypo | Self Monitoring  | Insight Depth | Mechanism Qualit | Communication Ef | **Total** |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Claude Haiku | 30.0/30 | 0.0/8 | 4.8/8 | 4.8/6 | 3.6/6 | 6.0/6 | 6.4/8 | 8.0/8 | 0.0/10 | 7.0/10 | **70.6/100** |

## Study Forensics Audit

### Claude Haiku

**Classification:** `overclaim` [+] (gold: `overclaim`)
**Finding Recall:** 50%
**Matched Findings:** conclusion_exceeds_results
**Missed Findings:** unsupported_generalization
**Extra Findings:** cautious_scope_control, none_or_minor, decorative_uncertainty, mechanism_not_demonstrated, correlation_as_causation

## Reasoning Integrity Audit

### Claude Haiku
**Classification:** Correct but brittle reasoning
**Load-bearing steps:** 0 / 7

## Mechanism Analysis

### Claude Haiku
| Aspect | Status |
|--------|--------|
| Concept named | :x: none |
| Mechanism described | :x: (0 sentence(s)) |
| Grounded to case | :x: (0 sentence(s)) |

**Missing:** concept not named, mechanism not described, mechanism not grounded to case data

## Grounding Audit

### Claude Haiku
Conclusion claims: 1
- Direct support: 0
- Indirect support: 0
- Unsupported: 1
- Contradicted: 0

**Unsupported claims:**
- "overclaim"


## Forensic Flags

### Claude Haiku

- **[MODERATE]** `weak_mechanism`: Correct answer but weak mechanism explanation — answer may not generalize
  - `final_answer`: "overclaim"
- **[MAJOR]** `unsupported_leap`: Correct answer with weak support chain — final answer may be an unsupported leap
- **[MODERATE]** `unsupported_conclusion_claims`: 1/1 conclusion claims lack step support
  - `final_answer`: "overclaim"


## Evidence Map

### Claude Haiku

**Correctness:** 30.0/30
  - (+) `final_answer`: "overclaim"
    _Agent's answer for correctness check_
  - Note: Exact match

**Support Strength:** 0.0/8
  - (-) `final_answer`: "overclaim"
    _Conclusion not supported by steps_
  - Note: Support classification: 0 load-bearing, 0 supporting, 0 mentioned / 7
  - Note: Reasoning graph: conclusion not well grounded

**Structural Reasoning:** 4.8/8
  - (+) `steps[6]`: "CLASSIFICATION DECISION: The primary problem is not modest hedging with an evidence-tier mismatch (mechanism_vs_evidence"
    _Most informative reasoning step_
  - Note: 7 reasoning steps
  - Note: Low step utility: 0/7 steps contribute

**Assumption Discipline:** 4.8/6
  - (+) `assumptions[2]`: "LDL cholesterol is a validated surrogate endpoint for cardiovascular outcomes in this population"
    _Most substantive assumption_
  - Note: 4/4 substantive assumptions

**Uncertainty Handling:** 3.6/6
  - (+) `uncertainties[2]`: "The exact regulatory pathway being pursued. 'Accelerated approval' can mean different things; some pathways do allow app"
    _Most substantive uncertainty_
  - (+) `confidence`: "confidence: 0.92"
    _Stated confidence level_
  - (-) `uncertainties[1]`: "Whether the 65% reduction is clinically meaningful in absolute terms or only relative terms. A large relative reduction "
    _Listed but never addressed in reasoning_
  - Note: 4 uncertainties (4 substantive)
  - Note: 1 decorative uncertainty(ies)

**Alternative Hypothesis Quality:** 6.0/6
  - (+) `alternative_hypotheses[0]`: "mechanism_vs_evidence: If the text had been more cautious (e.g., 'LDL reduction may eventually lead to cardiovascular be"
    _Most substantive alternative hypothesis_
  - Note: 3 alternative hypotheses considered
  - Note: 3/3 include rejection reasoning

**Self Monitoring Quality:** 6.4/8
  - (+) `self_check[4]`: "Did I confuse mechanism_vs_evidence with overclaim? No. The distinction is: mechanism_vs_evidence is when a text makes m"
    _Most substantive self-verification step_
  - Note: 6 self-check items
  - Note: Self-check quality: 0 deep, 6 arithmetic, 0 fluff

**Mechanism Quality:** 0.0/10
  - Note: Neither names concept nor explains mechanism

**Communication Efficiency:** 7.0/10
  - Note: Signal density: 0.69, 844 words
  - Note: Verbose (844 words)

**Insight Depth:** 8.0/8
  - (+) `(output text)`: "al. this is tier 3 (biomarker/surrogate endpoint), not clinical outcomes. conc"
    _Insight 'surrogate endpoint' matched (exact)_
  - Note: Key insights: 2 full / 2


## Failure Analysis

### Claude Haiku

**MODERATE:**
- **Unsupported Conclusion** `[MEDIUM CONFIDENCE]`: Final answer lacks load-bearing or supporting step grounding
  - `final_answer`: "overclaim"
  - _Impacts: support_strength_
- **Unsupported Intermediate Step** `[MEDIUM CONFIDENCE]`: No reasoning step is load-bearing — final answer lacks traceable derivation
  - `final_answer`: "overclaim"
  - _Impacts: support_strength, structural_reasoning_
- **Missed Key Insight** `[MEDIUM CONFIDENCE]`: Missed expected finding: unsupported_generalization
  - `(task expectation)`: "Expected: unsupported_generalization"
  - _Impacts: insight_depth_

**STYLISTIC:**
- **Decorative Uncertainty** `[HEURISTIC]`: Uncertainty 'Whether the 65% reduction is clinically meaningful in absolu...' is listed but not addressed
  - `uncertainties[1]`: "Whether the 65% reduction is clinically meaningful in absolute terms or only relative terms. A large"
  - _Impacts: uncertainty_handling_
- **Oververbose Without Gain** `[HEURISTIC]`: Output is verbose (844 words, density 0.69)
  - `(computed)`: "844 words, density 0.69"
  - _Impacts: communication_efficiency_


## Consistency & Grounding Audit

### Claude Haiku

- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 1 has low overlap with final answer (0/15 content words)
  - `key_claims[0]`: "The company uses outcome-level language ('transform outcomes,' 'cardiovascular protection,' 'major b"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 2 has low overlap with final answer (0/12 content words)
  - `key_claims[1]`: "No cardiovascular events were tracked in the trial, and no outcomes data will be available for 4+ ye"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 3 has low overlap with final answer (0/12 content words)
  - `key_claims[2]`: "The company is seeking accelerated approval based on a surrogate endpoint without outcomes validatio"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 4 has low overlap with final answer (0/13 content words)
  - `key_claims[3]`: "The 12-week duration is too short to assess long-term safety or durability, yet the company makes br"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 5 has low overlap with final answer (0/16 content words)
  - `key_claims[4]`: "The rhetorical inflation (promotional language) is the primary forensic problem, not merely a hedgin"
- **[WARN]** `[HEURISTIC]` `decorative_uncertainty`: Uncertainty 2 appears decorative — not addressed in reasoning or self-check
  - `uncertainties[1]`: "Whether the 65% reduction is clinically meaningful in absolute terms or only relative terms. A large"


## Agent Profiles

### Claude Haiku (claude-haiku-4-5-20251001)
**Parse OK:** True | **Latency:** 17185ms

**Final Answer:** overclaim

**Confidence:** 0.92

**Assumptions:**
- The Phase 2 trial is a legitimate randomized controlled trial with appropriate controls
- The 65% LDL reduction is accurately measured and statistically significant
- LDL cholesterol is a validated surrogate endpoint for cardiovascular outcomes in this population
- The company's statements represent the primary claims being made to the public and regulators

**Reasoning Steps:**
1. EVIDENCE TIER IDENTIFICATION: The study measured biomarkers (LDL cholesterol, liver safety) over 12 weeks in a Phase 2 trial. This is Tier 3 (biomarker/surrogate endpoint), not clinical outcomes.
2. CONCLUSION TIER IDENTIFICATION: The company claims the drug will 'transform outcomes for patients at high risk of heart attack and stroke' — this is Tier 5 language (human therapeutic benefit, cardiovascular event reduction).
3. BRIDGE GAP ANALYSIS: There is a two-tier gap. LDL reduction is a surrogate marker; cardiovascular event reduction is the actual clinical outcome. While LDL is a validated risk factor, the causal pathway from LDL reduction to event reduction is not proven in THIS population with THIS drug.
4. RHETORICAL INFLATION CHECK: The text uses promotional language: 'major breakthrough,' 'transform outcomes,' 'cardiovascular protection.' These are outcome-level claims, not biomarker-level claims. The company is actively selling clinical benefit.
5. CONFOUNDING CONTEXT: The trial is only 12 weeks long. Long-term safety, adherence, and durability are unknown. The company explicitly states no outcomes trial is expected for 4+ years — they themselves acknowledge the evidence gap.
6. ACCELERATED APPROVAL PATHWAY: The company is seeking regulatory approval based on a surrogate endpoint without outcomes data. This is a red flag for premature clinical translation.
7. CLASSIFICATION DECISION: The primary problem is not modest hedging with an evidence-tier mismatch (mechanism_vs_evidence). Rather, the company is making ACTIVE, PROMOTIONAL claims about clinical transformation and cardiovascular protection based on biomarker data alone. This is rhetorical inflation beyond the evidence tier. The language 'major breakthrough' and 'transform outcomes' are outcome-level claims unsupported by outcome data.

**Key Claims:**
- The company uses outcome-level language ('transform outcomes,' 'cardiovascular protection,' 'major breakthrough') to describe a biomarker-level finding (LDL reduction).
- No cardiovascular events were tracked in the trial, and no outcomes data will be available for 4+ years. This is a two-tier evidence gap.
- The company is seeking accelerated approval based on a surrogate endpoint without outcomes validation, which is a regulatory red flag.
- The 12-week duration is too short to assess long-term safety or durability, yet the company makes broad claims about patient outcomes.
- The rhetorical inflation (promotional language) is the primary forensic problem, not merely a hedging failure. The company is actively selling clinical benefit it has not demonstrated.

**Alternative Hypotheses:**
- mechanism_vs_evidence: If the text had been more cautious (e.g., 'LDL reduction may eventually lead to cardiovascular benefits, pending outcomes trials'), the primary issue would be the tier gap, not the rhetoric. But the actual language is promotional.
- solid: If the company had claimed only 'significant LDL reduction in a Phase 2 trial' and explicitly stated 'cardiovascular benefits remain to be proven,' this would be solid. But they did not.
- correlation_vs_causation: Not the primary issue here, because LDL and cardiovascular events are known to be causally related. The problem is that THIS drug's effect on events is unproven, not that LDL and events are uncorrelated.

**Uncertainties:**
- Whether the Phase 2 trial had appropriate controls (e.g., placebo or active comparator). The summary does not specify, but Phase 2 trials typically do.
- Whether the 65% reduction is clinically meaningful in absolute terms or only relative terms. A large relative reduction from an already-low baseline might be less impressive.
- The exact regulatory pathway being pursued. 'Accelerated approval' can mean different things; some pathways do allow approval on surrogate endpoints if the surrogate is well-validated. However, the company's own statement that outcomes data will take 4+ years suggests they are not confident in the surrogate alone.
- Whether LDL reduction of this magnitude in statin-refractory patients has prior evidence of cardiovascular benefit. If it does, the claim is stronger; if not, it is weaker. The summary does not provide this context.

**Self-Verification:**
- Did I correctly identify the evidence tier? Yes — biomarker (LDL reduction) is Tier 3.
- Did I correctly identify the conclusion tier? Yes — 'transform outcomes' and 'cardiovascular protection' are Tier 5 (clinical outcomes).
- Is the bridge gap real? Yes — LDL is a surrogate; cardiovascular events are the actual outcome. The company itself acknowledges this by planning a 4-year outcomes trial.
- Is the rhetorical inflation real? Yes — 'major breakthrough' and 'transform outcomes' are outcome-level claims, not biomarker-level claims. This is not cautious language.
- Did I confuse mechanism_vs_evidence with overclaim? No. The distinction is: mechanism_vs_evidence is when a text makes modest claims but rests on the wrong evidence tier (e.g., 'this mouse study suggests a potential mechanism for human disease'). Overclaim is when a text makes inflated claims beyond the evidence tier (e.g., 'this mouse study proves the drug works in humans'). This text uses promotional language ('major breakthrough,' 'transform outcomes') to describe a biomarker finding, which is overclaim.
- Did I miss any solid aspects? The company did acknowledge that outcomes data are pending, which is a hedge. However, this hedge does not resolve the overclaim; it only acknowledges the gap while still making the inflated claims.

**Dimension Scores:**
- Correctness: 30.0/30 `##########`
- Support Strength: 0.0/8 `..........`
- Structural Reasoning: 4.8/8 `######....`
- Assumption Discipline: 4.8/6 `########..`
- Uncertainty Handling: 3.6/6 `######....`
- Alternative Hypothesis Quality: 6.0/6 `##########`
- Self Monitoring Quality: 6.4/8 `########..`
- Insight Depth: 8.0/8 `##########`
- Mechanism Quality: 0.0/10 `..........`
- Communication Efficiency: 7.0/10 `#######...`


## Final Verdict

**Solo run: Claude Haiku** scored **70.6/100**.

**Best per dimension:**
- Correctness: Claude Haiku (30.0/30)
- Support Strength: Claude Haiku (0.0/8)
- Structural Reasoning: Claude Haiku (4.8/8)
- Assumption Discipline: Claude Haiku (4.8/6)
- Uncertainty Handling: Claude Haiku (3.6/6)
- Alternative Hypothesis Quality: Claude Haiku (6.0/6)
- Self Monitoring Quality: Claude Haiku (6.4/8)
- Insight Depth: Claude Haiku (8.0/8)
- Mechanism Quality: Claude Haiku (0.0/10)
- Communication Efficiency: Claude Haiku (7.0/10)

**Latency vs Quality:**

| Agent | Latency | Score | Points/sec |
|-------|---------|-------|------------|
| Claude Haiku | 17.2s | 70.6/100 | 4.1 |

Failure modes observed: decorative_uncertainty, missed_key_insight, oververbose_without_gain, unsupported_conclusion, unsupported_intermediate_step.
